Bristol-Myers Squibb Co vs S&P Global Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B), while S&P Global Inc trades at $409.5 (market cap $120.48B). The key difference: Bristol-Myers Squibb Co and S&P Global Inc are close in size by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | SPGI | |
|---|---|---|
Market Cap | $129.94B | $120.48B |
Sector | Health | Financials |
52-Week High | $65.89 | $534.79 |
52-Week Low | $42.60 | $370.42 |
Enterprise Value | $163.92B | $131.97B |
Dividend Yield | 3.96% | 0.95% |
Trailing returns across standard periods
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →